咪唑斯汀两种服药方法治疗慢性荨麻疹疗效及控制复发临床观察

Clinical study on curative effect of mizolastine two different delivery methods for chronic urticaria

目的观察咪唑斯汀缓释片两种服药方法治疗慢性荨麻疹及控制复发的效果。方法 107例慢性荨麻疹患者随机分为两组,A组48例,必要时口服咪唑斯汀,服药剂量24h不超过10mg;B组59例,连续服用咪唑斯汀,10mg/d,共观察8周。在治疗前、治疗后1、2、4、8周及停药后第3d、1周、2周对两组患者的症状和体症进行评分。结果两组患者在治疗期间,总体症状控制早期B组优于A组,但随着时间推移,差距逐渐缩小,且对控制瘙痒症状差异不显著。在控制复发方面,1周后两组无明显差异。结论治疗慢性荨麻疹以控制瘙痒为主,必要时采取口服咪唑斯汀可减少用药次数、用量和不良反应的发生。

Objective To observe the effect of two different delivery methods of mizolastine sustained release tablets for chronic urticaria. Methods One hundred and seven cases with chronic urticaria were randomly divided into two groups. The patient enrolled in group A （n=48） was given one tablet ofmizolastine sustained release tablet only when necessary, while the patient enrolled in group B （n=59） was given one tablet of mizolastine sustained release tablet per day for 8 weeks continously. Efficacy evaluation was executed at different timepoints before and after the start of the treatment. Results Comparing with group A, the patients in group B showed a better curative effect in the general symptom control during the early stage of the treatment, but the difference between the two groups became more and more smaller with the treatment time went by. There no difference in itching control and relapse prevention between the two groups. Conclusion The main purpose of chronic urticaria therapy is to control itching symptom, taking mizolastine sustained release tablet only when necessary, can reduce the dosage of medication and the incidence of adverse reactions.